MATINAS BIOPHARMA HOLDINGS, INC. Impairment of Intangible Assets, Finite-lived
MATINAS BIOPHARMA HOLDINGS, INC. (MTNB) reported Impairment of Intangible Assets, Finite-lived of $2.34 million for the 12-month period ending 2024-12-31, per its 10-K filed 2026-03-31.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ImpairmentOfIntangibleAssetsFinitelived · last filed 2026-03-31
- MATINAS BIOPHARMA HOLDINGS, INC. impairment of intangible assets, finite-lived for fiscal 2024 was $2.34M.
| Period end | Impairment of Intangible Assets, Finite-lived 12 month |
|---|---|
| 2024-12-31 | $2.34M 10-K · filed 2026-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| Nexentis Technologies Inc. (NXTS) | $0.002B |